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Tumour cells exist at various levels of oxygenation and can there-
fore respond differently to a given dose of radiation. Since
Thomlinson and Gray (1955) first observed cords of viable cells
surrounding blood vessels in histological tumour sections,
numerous studies have focused on strategies designed to target
chronically hypoxic tumour cells. More recently, it has been postu-
lated that tumour cell subpopulations at intermediate levels of
oxygenation may also have a large impact on tumour response to
radiation (Wouters and Brown, 1997). The possibility of targeting
intermediately oxygenated cells, and the resultant effect that
destroying these cells would have on overall tumour radiosensi-
tivity, are avenues of research that need to be explored. Altering
tumour perfusion to favour increased oxygen delivery to interme-
diately hypoxic cells prior to therapeutic irradiation may have an
important impact on solid tumour response to radiation. The
calcium channel blocker diltiazem and the haemorrheologic agent
pentoxifylline were used as tools in order to study the effects that
changes in tumour perfusion have on the radiosensitivity of
various subpopulations of tumour cells. 
Calcium channel blockers have the general ability to affect
calcium-mediated cellular processes by blocking the uptake of
calcium ions through plasma membrane receptors (Greenberg,
1987). Benzothiazepine-derived calcium channel blockers, such
as diltiazem hydrochloride, act primarily to dilate the principal
coronary arteries and some systemic arteries, resulting in a
decrease in total peripheral resistance and systemic blood pres-
sure (Arcuri et al, 1998a). Diltiazem has been shown to increase
tumour perfusion and tumour cell radiosensitivity in SCCVII/St
tumours (Wood and Hirst, 1989). Diltiazem also increased tumour
perfusion and oxygenation in the Ehrlich ascites tumour model,
which was correlated with tumour regression after irradiation
(Muruganandham et al, 1999). 
Pentoxifylline is a dimethylxanthine derived hemorrheologic
agent that has been shown to increase the deformability of red
blood cells and leukocytes (Ehrly, 1978; Armstrong et al, 1990;
Arcuri et al, 1998b). These observations are important when
considering the increased blood cell rigidity and associated
increase in blood viscosity that can result from exposure of blood
cells to the hypoxic conditions found in many tumours (Van
Nueten and Vanhoutte, 1980; Hakim and Macek, 1988). Decreas-
ed flow through tortuous tumour vasculature can make micro-
regions of the blood hypoxic as the tumour tissue utilizes the
available oxygen. The concomitant decrease in micro-regional
blood pH decreases the flexibility of blood cells, which further
impairs blood flow through the narrow vessels. Administration
of pentoxifylline can result in an increased flexibility of blood
cells (with a decrease in whole blood viscosity) that can increase
blood flow through narrow tumour vasculature. Pentoxifylline
has been shown to decrease interstitial fluid pressure and
increase net tumour perfusion, oxygenation, and net radiosensi-
tivity in various experimental tumour systems (Lee et al, 1992,
1993, 1994; Song et al, 1992, 1994; Honess et al, 1993, 1995;
Kelleher et al, 1998). 
We studied diltiazem and pentoxifylline-induced alterations in
the perfusion and radiosensitivity of SiHa and WiDr human
tumour xenografts. Alterations in net tumour perfusion were
measured using a modified 86Rb extraction method, while changes
in the micro-regional distribution of tumour blood flow were
studied using a dual staining mismatch technique. When combined
with information from an in vivo–in vitro cloning assay including
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fluorescence-activated cell sorting (FACS) analysis, our data
address the degree to which drug-induced alterations in tumour
macro- and micro-perfusion can affect the radiosensitivity of
tumour cell subpopulations. 
MATERIALS AND METHODS 
Mice and tumours 
The tumours were derived from SiHa, a human cervical squamous
cell carcinoma (Friedl et al, 1970) and WiDr, a human colon
adenocarcinoma (Noguchi et al, 1979), cell lines. Both were
obtained as cultured cell lines (ATCC, Rockville, Maryland),
grown in SCID mice, and maintained by intramuscular transplant.
Experimental tumours were grown as dorsal subcutaneous
implants in NOD-SCID mice (bred in-house) for all perfusion,
mismatch and sorting experiments. All procedures were per-
formed in accordance with the ethical standards of the University
of British Columbia Committee on Animal Care and the Canadian
Council on Animal Care, which conform in every way to the
UKCCR Guidelines (UKCCR, 1998). 
Drugs 
The drugs diltiazem hydrochloride (ICN Biomedicals, Costa
Mesa, California) and pentoxifylline (Sigma, Oakville, Ontario)
were dissolved in PBS on the day of each experiment. The appro-
priate drug concentrations were delivered in an i.p. injection
volume of 0.01 ml–1 gram body weight. 
Modified 86rubidium extraction technique 
The classical 86rubidium (86Rb) extraction method is based on
the observation that after a bolus injection of 86rubidium chloride
(86RbCl) into the bloodstream of an experimental animal, the
uptake of the isotope by each tissue is proportional to the fraction
of the cardiac output flowing through that tissue (Sapirstein,
1958). Gullino and Grantham (1961) validated the method for
measuring net blood flow in implanted tumours. A primary limi-
tation of the technique is that each blood flow determination is
terminal, and therefore only a single perfusion measurement
can be performed in a given animal. We developed a modified
86Rb extraction method to enable multiple tumour blood flow
measurements in the same mouse. The procedure allowed one
perfusion measurement as a control or baseline value without
sacrifice of the animal. A blood flow-modifying agent could
then be administered and a second perfusion determination
performed. Each animal (and tumour) was therefore used as its
own control. 
86Rubidium chloride (Amersham Pharmacia Biotech,
Buckinghamshire, England) was diluted in PBS to an activity of 
~ 3.7 MBq of 86Rb per 0.1 ml injection. The method involved the
use of a solid-state radiation detection probe externally positioned
over the implanted tumour during each of 2 sequential intravenous
injections of 86RbCl (Figure 1). The animal was treated with the
appropriate concentration of drug at a given time before the
second  86RbCl injection. Activity from the tumour area was
measured for 90 s after each isotope injection, which has previ-
ously been established as the time in which tumour uptake of 86Rb
is at a plateau (Zanelli and Fowler, 1974). After a short period of
time, the residual tumour activity from the first 86RbCl injection
would not be representative of tumour blood flow since significant
amounts of the isotope would have recirculated and redistributed
throughout the animal. Therefore the activity remaining from the
first 86RbCl injection was used as the background radiation signal
for the second injection. The radioactivity of the tail was also
measured after each injection in order to determine the amount of
injection solution that remained at the injection site. Mice were
excluded from analysis if the activity remaining in the tail from
either  86RbCl injection was more than 10% of the injected
activity. 
Animals were killed by cervical dislocation 90 s after the
second isotope injection. The tumour and skin overlying the
tumour were excised, weighed and the radioactivities measured
in a Cobra II AutoGamma well-type radiation counter (Packard
Instrumentals, Meriden, Connecticut). The external radioactivity
signal from the tumour area was normalized for the skin over-
lying the tumour to provide a radioactivity estimate for the
tumour alone. Data are expressed in terms of the percentage
of injected activity per gram of tumour tissue, which is propor-
tional to the percentage of the cardiac output per gram of tissue
(%CO g–1). 
Dual staining mismatch 
The micro-regional distribution of tumour blood flow was assessed
via a dual-staining mismatch technique designed to observe tran-
sient alterations in tumour perfusion (Trotter et al, 1989a, 1989b).
The fluorescent bisbenzimide dye Hoechst 33342 (0.5 mg per
mouse delivered in 0.05 ml PBS) was administered by intravenous
injection to a tumour-bearing mouse, followed 35 min later by i.v.
injection of the carbocyanine derivative DiOC7 (0.1 mg per mouse
in 0.05 ml 75% DMSO). Pentoxifylline was injected intraperi-
toneally at 15 or 30 min before DiOC7 injection. The animals were
sacrificed 5 min after carbocyanine injection and the tumours were
excised, embedded, frozen and sectioned. The Hoechst and carbo-
cyanine stains were thus allowed to perfuse the tumour for at least 5
minutes before drug treatment or tumour excision respectively.
This experimental design allowed the staining pattern from the first
dye to be quantitatively compared with alterations in the delivery of
the second dye induced by the pentoxifylline treatment (Figure 2).
Representative microscopic images of the tumour sections were
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Figure 1 Experimental apparatus for the modified 86RbCl extraction
procedure. The lead shield was designed with an aperture so the
radioactivity signal from the tumour area could be isolated from the overall
radioactivity of the animal. The signal from the tumour area is normalized for
activity from the skin overlying the tumour (see text) Tumour perfusion and radiosensitivity 1579
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digitized and analysed by locally developed software for the fluo-
rescent image processing system (FIPS) (Durand and LePard,
1994, 1995). 10 images were collected for each tumour and the
FIPS data were averaged to allow comparison of perfusion
changes between various tumour regions. 
Differences in staining profiles were quantified using a multi-
step algorithm to facilitate statistical analysis. Briefly, when the
fluorescence intensity of either stain exceeded background, the
relative intensity of the carbocyanine staining was compared with
the Hoechst staining. Variation by less than a factor of 2 was
defined as a ‘0% change’, a 2–3-fold increase in DiOC7 staining
relative to Hoechst staining was defined as a ‘+100% change’,
etc. Similarly, decreased relative carbocyanine intensities were
expressed as negative percentage changes. Percentage changes
exceeding ±300% (i.e. >4-fold changes in relative DiOC7 inten-
sity) roughly corresponded to our previous visual criteria for stain
mismatch (Trotter et al, 1989a, 1989b). 
Fluorescence-activated cell sorting and in vivo–in vitro
cloning assay 
Drug-induced alterations in tumour radiosensitivity were
assessed by an in vivo–in vitro cloning assay. Fluorescence-
activated cell sorting as part of a cloning assay provides information
on the radiosensitivity of various subpopulations of cells within
a tumour (Durand, 1994). After X-irradiation, tumour cells can
be sorted based on the cellular content of an intravenously
injected perfusion stain. By subsequently plating the resultant
cell fractions in a cloning assay (Chaplin et al, 1985; Olive et al,
1985; Durand, 1986), the radiosensitivities of various tumour
cell subpopulations can be determined. Thus rather than
obtaining a net radiosensitivity measurement for an entire
tumour from an in vivo–in vitro cloning assay, sorting the
tumour cells prior to plating provides information regarding the
responses of specific tumour cell subpopulations to a given
radiotherapy adjuvant. 
Briefly, the animals were treated with the appropriate drug at
varying times before whole body 250 keV X-irradiation with a
dose rate of 3 Gy min–1. Immediately post-irradiation, animals
were injected with Hoechst 33342 (1 mg in 0.05 ml PBS) into
the lateral tail vein and the tumours were excised 20 min later.
This stain concentration was nontoxic to host animals and tumour
cells. Excised tumours were washed in ice-cold PBS in order to
remove any stain released by the excision process and to inhibit
redistribution of the Hoechst. The tumour was finely minced
before agitation in an enzyme suspension of 0.5% trypsin and
0.08% collagenase at 37˚C for 40 min; 0.06% DNAse was then
added. The cell suspension was gently vortexed, filtered through
a 30 µ m nylon mesh to remove clumps, and the monodispersed
cells were washed and processed through a FACS 440 (Becton
Dickinson, Mountain View, California) flow cytometer. Cells
were defined on the basis of forward scatter (cell size) and sort
windows were automatically set to subdivide the cell population
into 8 fractions of differing intracellular Hoechst concentrations
(Durand, 1986). The primary assumption of the method is that the
Hoechst staining profile of a tumour simulates the oxygenation
profile during irradiation. This assumption is valid provided that
the time between irradiation and Hoechst injection is short, and
that any significant changes in tumour perfusion are sufficiently
slow so as not to occur between tumour irradiation and stain
injection. 
Predetermined numbers of cells were sorted into test tubes
containing culture medium. The tubes were then poured and rinsed
into 100 mm tissue culture dishes and incubated in 94% air plus
6% CO2 for 2 weeks to allow colony formation. All in vitro tech-
niques used minimal essential medium containing 10% fetal bovine
serum and antibiotics. No special additives were used for tumour
cell culture, nor were feeder cells, gel cultures, or low oxygen
tensions found to improve cell growth or viability of these cell lines
(note that these human tumour cell lines were initially selected
in tissue culture). In all clonogenicity data presented, we have
plotted the ratio of observed colonies to cells plated without
correcting for control plating efficiencies (which were in the
20–30% range). 
Statistics 
Statistical tests were conducted using SPSS software (SPSS Inc.,
Chicago, Illinois). 2-sample student’s t-tests were used to analyse
the dual-staining mismatch and radiosensitivity data. 
RESULTS 
Alterations in net tumour perfusion 
The modified 86Rb extraction technique was used to determine the
doses of each drug that would yield observable increases in net
tumour blood flow. Diltiazem did not significantly increase net perfu-
sion in SiHa or WiDr tumours at doses between 2 and 20 mg kg–1
(data not shown). The largest (non-significant) increases in net
tumour perfusion for SiHa and WiDr tumours were at diltiazem doses
of 5 mg kg–1 and 2 mg kg–1 respectively. Pentoxifylline increased net
tumour perfusion in SiHa tumours at a dose of 5 mg kg–1, though the
increase was not statistically significant (Figure 3A). A decrease in
SiHa net tumour blood flow was also observed 15 minutes after 20
mg kg–1 pentoxifylline, but the decrease was not significant and did
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Figure 2 Schematic for the dual-staining mismatch protocol. Tumour areas
that stained more brightly with carbocyanine relative to Hoechst (i.e. positive
intensity changes) were adjacent to blood vessels that ‘opened’ during the
time interval. Tumour areas that stained less brightly with carbocyanine
relative to Hoechst (i.e. negative intensity changes) were adjacent to blood
vessels that ‘closed’ during the time interval. Tumour areas that had
‘matched’ staining patterns were adjacent to blood vessels that did not
increase or decrease perfusion by more than 2-fold during the time between
dye injections 1580 KL Bennewith and RE Durand 
British Journal of Cancer (2001) 85(10), 1577–1584 © 2001 Cancer Research Campaign
not yield an observable effect on SiHa tumour radiosensitivity (data
not shown). Net tumour perfusion was increased in WiDr tumours by
130±40% (mean ± SEM) 15 minutes after administration of 50 mg
kg–1 pentoxifylline (Figure 3A). 
The above drug concentrations were used in order to determine
the time after drug administration that would yield the greatest
increase in net tumour perfusion. Diltiazem did not significantly
improve net tumour perfusion at 5 mg kg–1 in SiHa tumours or 
2 mg kg–1 in WiDr tumours at 15, 30, 60 or 120 minutes after drug
administration (data not shown). The pentoxifylline-induced
increases in net tumour perfusion observed 15 min after drug
administration were short-lived in both SiHa and WiDr tumours.
Specifically, for WiDr tumours the net tumour perfusion 30 min
after drug administration was not significantly different from
control levels (Figure 3B). 
Alterations in the micro-regional distribution of tumour
blood flow 
Micro-regional changes in tumour blood flow were studied 15
and 30 min after administration of pentoxifylline. The distribu-
tion of SiHa tumour perfusion was not significantly affected by
administration of 5 mg kg–1 pentoxifylline (Figure 4A). Subtle
redistributions of WiDr tumour perfusion were observed 15 and
30 minutes after 50 mg kg–1 pentoxifylline administration when
compared to tumours that were not treated with drug between
stain injections (Figure 4B). In the WiDr tumours, there was a
general decrease in the percentage of vessels that showed reduced
perfusion and an increase in the percentage of vessels that showed
increased perfusion between stain injections. The increases in
microregional perfusion 30 minutes after drug administration
were statistically significant (P ≤ 0.05). There was also a decrease
in the percentage of vessels that exhibited less than 2-fold
changes in perfusion. These data suggest that the pentoxifylline
increased blood flow through tumour vessels that would not
normally exhibit changes in perfusion over the measurement
interval. 
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Figure 3 Relative net tumour perfusion measured by the modified
86Rb extraction method. (A) Relative net tumour perfusion measured
15 minutes after administration of various doses of pentoxifylline (PENTO).
SiHa tumours did not demonstrate a significant increase in net perfusion
with doses of PENTO between 5 and 50 mg kg–1. A decrease in net SiHa
tumour perfusion was observed at 20 mg kg–1 PENTO, but the decrease
was not associated with a concomitant alteration in tumour cell
radiosensitivity (see text). WiDr tumours exhibited an approximately linear
dose response to PENTO with a maximal observed increase in net tumour
perfusion of 130% ± 40% (mean ± SEM) with a dose of 50 mg kg–1. 
n = 3–5 animals per data point. (B) Relative net perfusion of WiDr tumours
measured at various times after administration of 50 mg kg–1 pentoxifylline.
The increase in net WiDr perfusion observed at 15 minutes returned
to control values by 30 minutes after drug dosing. n = 3–5 animals per 
data point 
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Figure 4 Dual-staining mismatch data showing alterations in the micro-
regional distribution of tumour perfusion 15 and 30 minutes after
administration of pentoxifylline (PENTO). (A) SiHa tumours did not
demonstrate statistically significant alterations in micro-regional perfusion
after administration of 5 mg kg–1 pentoxifylline. n = 6 animals per graph. (B)
WiDr tumours demonstrated statistically significant increases in micro-
regional tumour perfusion 30 minutes after administration of 50 mg kg–1
pentoxifylline. n = 8–10 animals per graph (* P ≤ 0.05) Tumour perfusion and radiosensitivity 1581
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Alterations in tumour radiosensitivity 
For the cloning assays, the most brightly staining tumour cells
(fraction 1) were proximal to functional vasculature and thus
represented the cells that were most aerobic during irradiation.
Similarly, the most dimly staining tumour cells (fraction 8) were
distant from functional vasculature in the tumour and represented
the cells that were the least oxygenated. Since we generally
consider 2 principal mechanisms of hypoxia generation in
solid tumours, the intermediate sort fractions would contain cells
that arose from both chronically and transiently hypoxic condi-
tions. The intermediate sort fractions typically represent those
cells that existed at static levels of intermediate oxygenation,
receiving intermediate levels of stain due to their distance from
functional vasculature. In tumours with significant amounts of
transient hypoxia however, such as WiDr tumours, intermediate
sort fractions can also represent cells that changed oxygenation
level during the lifetime of the Hoechst in the circulation (T1/2 for
Hoechst in murine circulation is 110 seconds (Olive et al, 1985)).
With extreme changes in blood vessel perfusion during the circula-
tion lifetime of the Hoechst stain, transiently hypoxic cells may
also be present in the most brightly and most dimly staining cell 
fractions. 
SiHa tumour-bearing mice and WiDr tumour-bearing mice were
given 5 mg kg–1 and 2 mg kg–1 diltiazem at various times prior to
single irradiation doses of 5 Gy and 10 Gy, respectively. All drug
concentrations were chosen based on the maximal increases in net
tumour perfusion observed by 86Rb extraction. As would be
expected from the net perfusion data, there were no significant
increases in tumour cell radiosensitivity when diltiazem was
administered at these doses 15 min to 2 h prior to irradiation of
either tumour type (data not shown). 
SiHa tumour-bearing mice were given 5 mg kg–1 pentoxi-
fylline at various times prior to a single irradiation dose of 5 Gy.
The in vivo–in vitro cloning assay data did not indicate any
significant changes in tumour cell radiosensitivity between 15
min and 2 h after drug treatment when compared to control mice
that received radiation alone (Figure 5A). 
WiDr tumour-bearing mice were given 50 mg kg–1 pentoxi-
fylline at various times prior to a single irradiation dose of 10 Gy.
The in vivo–in vitro cloning assay data indicated increases in the
radiosensitivity of tumour cell subfractions 15 and 30 min after
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drug administration (Figure 5B). Specifically, the cells that corre-
sponded to intermediate levels of oxygenation exhibited statisti-
cally significant increases in radiosensitivity with pentoxifylline
treatment prior to irradiation (P ≤ 0.05). A less marked, non-
statistically significant increase in tumour cell radiosensitivity
was also observed in the most brightly staining tumour cells. No
significant increase in radiosensitivity was observed in the dimmest
staining fractions of tumour cells, indicating that the pentoxifylline
had no observable radiosensitizing effect on the diffusion-limited
hypoxic cells. Since the chronically hypoxic WiDr tumour cells
were not affected by the pentoxifylline, the intermediately
staining cells that demonstrated pentoxifylline-induced increases
in radiosensitivity were most likely transiently hypoxic cells. 
DISCUSSION 
Many radiosensitizing drugs have been studied in pre-clinical
laboratories as potential adjuvants to radiotherapy. However, there
is a limitation to the use of certain agents in that the efficacy of
some drugs (as with many chemotherapy agents used to treat
primary tumour masses) can be limited by the delivery of the
active agent to poorly vascularized tumour regions. Thus an
important advantage that drugs such as diltiazem and pentoxi-
fylline have over various other radiosensitizing agents is that the
activities of the drugs are not limited by delivery to poorly
perfused regions of a tumour mass. 
When interpreting the effects of diltiazem or pentoxifylline on
the perfusion of experimental tumours, one must consider the
tumour system in which the measurements have been performed.
Xenografts that have been derived from different cell lines can
have very different characteristics in terms of their hypoxic frac-
tion and intrinsic radiosensitivity. In our hands, SiHa tumours
demonstrate little evidence of transient changes in perfusion while
WiDr tumours are known to contain a relatively large hypoxic
fraction consisting of both chronically and transiently hypoxic
cells. In addition, sections of SiHa tumours examined microscopi-
cally contain larger diameter blood vessels on average than WiDr
tumours (data not shown). Thus the narrower vasculature, coupled
with the greater hypoxic fraction, in WiDr tumours would be
expected to promote a higher level of perfusion-limited hypoxia
when compared to SiHa tumours. The intrinsic differences
between the hypoxic content of SiHa and WiDr tumours allows
each to be used to assess the role of chronic versus acute hypoxia
in experimental tumour systems. 
Diltiazem did not induce any significant changes in net perfu-
sion of SiHa or WiDr tumours from 15 min to 2 h after adminis-
tration (data not shown). Our results are in contrast to other data
(Wood and Hirst, 1989; Muruganandham et al, 1999) which
suggest net tumour perfusion increases at doses between 2 mg
kg–1 and 100 mg kg–1 in other tumour systems. As would be
expected from our net perfusion data, there were no significant
increases in tumour cell radiosensitivity when diltiazem was
administered 15 min to 2 h prior to tumour irradiation (data not
shown). 
Given the accepted mechanism for diltiazem-induced increases
in tumour perfusion (i.e. by affecting systemic arteries), there
was no a priori expectation of differential perfusion effects on
SiHa versus WiDr tumours with diltiazem administration.
However, when considering the mechanism of pentoxifylline-
induced changes in tumour perfusion (i.e. by affecting blood cell
deformability and thereby allowing blood flow through narrower
vasculature), any differences in the functionality of tumour blood
vessels could impact potential changes in perfusion. Thus the
observation that WiDr tumours have more tortuous vasculature,
and hence more transient hypoxia, than SiHa tumours leads to
an expectation of dissimilar responses of the 2 tumours to
pentoxifylline. 
Pentoxifylline non-significantly increased the net perfusion of
SiHa tumours 15 min after a dose of 5 mg kg–1 (Figure 3A) and
there were no observed increases in net tumour perfusion from 30
min to 2 h after drug administration (data not shown). There were
also no observable increases in the radiosensitivity of any SiHa
tumour cell subpopulations when pentoxifylline was administered
prior to tumour irradiation (Figure 5A). Since SiHa tumours
contain relatively little transient hypoxia, the observation that
pentoxifylline did not influence SiHa radiosensitivity suggests the
drug did not increase the oxygenation level of chronically hypoxic
SiHa tumour cells. 
Pentoxifylline increased the net perfusion of WiDr tumours by
130 ± 40% (mean ± SEM) 15 min after administration of a dose
of 50 mg kg–1 (Figure 3A), and the net tumour blood flow
returned to control levels by 30 minutes (Figure 3B). The effec-
tive pentoxifylline dose of 50 mg kg–1 agrees with other published
data (Song et al, 1992, 1994; Honess et al, 1993; Kelleher et al,
1998), though the maximal values of increased tumour perfusion
varies among the tumour systems. The observed increase in net
tumour perfusion after 15 minutes correlated with an increase in
blood flow through partially occluded tumour blood vessels as
suggested by the dual-staining mismatch data (Figure 4B).
Interestingly, the redistribution of tumour perfusion on a micro-
regional level was found to be at least 30 min in duration even
though there was no observable increase in net tumour perfusion
at that time. These data suggest that micro-regional redistribu-
tions of tumour blood flow may not necessarily be associated
with concomitant changes in net tumour perfusion, and thus
may not be detectable via the 86Rb extraction method. Based
on the mismatch data, an increase in the oxygenation and
radiosensitivity of normally perfusion-limited hypoxic cells
would be expected up to 30 minutes after pentoxifylline adminis-
tration. 
The in vivo–in vitro cloning assay data showed increases in
WiDr tumour cell radiosensitivity when pentoxifylline was given
15 and 30 min prior to tumour irradiation (Figure 5B). When
considering the effect of pentoxifylline on the radiosensitivity of
different WiDr tumour cell subpopulations, the sort fractions that
corresponded to tumour cells at intermediate levels of oxygena-
tion exhibited statistically significant increases in radiosensitivity
(P ≤ 0.05). When taken with the dual staining mismatch data 30
minutes after drug administration, the pentoxifylline-induced
increase in the radiation response of intermediately staining
tumour cells was likely due to reoxygenation of perfusion-limited
hypoxic cells. The increase in WiDr radiosensitivity after 30 min
was of comparable magnitude to the increased radiosensitivity
associated with the net perfusion increase after 15 minutes. These
data suggest that the redistribution of tumour blood flow to
increase oxygen delivery to intermediately oxygenated cells is at
least as important as increasing net tumour blood flow in terms of
increasing the radiosensitivity of WiDr tumours. 
Determining the identity of cells that respond to a particular
therapeutic intervention has several implications for clinical
radiotherapy. For example, treatments designed to increase theTumour perfusion and radiosensitivity 1583
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net oxygen content of the blood during radiotherapy would be
expected to have a radiosensitization effect on chronically
hypoxic cells, but would not likely affect the response of cells
made transiently hypoxic by temporary fluctuations in tumour
perfusion (Chaplin et al, 1986). However, before strategies for
targeting specific cell subpopulations can be transferred to the
clinical situation, further characterization of tumour hypoxia is
necessary. Specifically, data regarding the presence of transient
hypoxia in clinical tumours has been anecdotal thus far, and
further studies are necessary to determine if transient hypoxia is
present in sufficient quantity to impact clinical tumour response
(Durand and Aquino-Parsons, 2001). 
The challenge of clinically targeting specific tumour cell
subpopulations is exacerbated by current definitions of tumour
response to therapy. In the clinical situation, tumours are generally
defined as ‘responsive’ to therapy when tumour shrinkage occurs.
Thus in order to observe a ‘response’ to therapy, a majority of
tumour cells must both die and disappear from the tumour bulk
during treatment. However, when considering the goal of tumour
‘cure’, kinetics studies in experimental tumours have shown that it
is essential that the minority of maximally resistant tumour cells
are also destroyed during treatment (Durand, 1993, 1994). The
difficulty inherent in defining a radiotherapy intervention that
affects a minority of tumour cells is evident in the clinical situation
so long as the majority of tumour cells dictate clinical tumour
‘response’. Thus the further refinement of pre-clinical and clinical
laboratory techniques designed to elucidate the responses of
specific tumour cell subpopulations to various therapeutic inter-
ventions is warranted. 
As suggested in a recent paper by Wouters and Brown (1997),
cells at intermediate levels of oxygenation may have a substantial
effect on the overall response of a tumour to radiation. Our data
support this assertion in that drug-induced redistributions of
tumour blood flow to favour increased oxygen delivery to interme-
diately oxygenated cells yielded increases in tumour cell response
to a large, single dose of radiation. However, the response of
tumours to multiple fractions of radiation administered in clinical
radiotherapy protocols may also be influenced by the presence of
transiently hypoxic cells. Further studies are necessary in order to
assess the presence and potential impact that transiently hypoxic
cells may have on tumour response to therapy. 
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